MMM · a US exchange · USD · Market cap $86.4B · 60,500 employees
3M Company provides diversified technology services in the America, the Asia Pacific, Europe, the Middle East, Africa, and internationally.
FAIL · Does not pass the screen
167.52 USD
At the last full screen 2026-09-08
Screened 2026-09-08 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
3M holds its Markdown at $167.52. Consolidating, no directional conviction, held for 258 days.
As held on the ledger · 2026-09-08
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 258 days
Price at the screen
$167.52
Valuation
29.75 trailing · 17.13 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.07
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.40%
Below 33%
Interest-bearing debt is 33.4% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
1.85%
Below 33%
Cash held in interest-bearing accounts and securities is 1.8% of assets, under the one-third limit.
Pass
Receivables
23.24%
Below 49%
Money owed to the company is 23.2% of assets, under the 49% limit.
Pass
Revenue purity
0.93%
Below 5%
Only 0.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Conscience Overlay
Conscience flag · AFSC Investigate
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on AFSC Investigate. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 16% discount to our $193.78 fair value, moderate competitive moat, 2.50% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 15.7% margin of safety to the base estimate.
Third-party analyst targets: 17 covering, consensus Buy. The average target sits +15% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
3M's Everyday Brands Mask Heavy Debt
Walk through any workshop or hospital and you will spot 3M products holding things together. The business still earns a solid 11 percent profit margin and posts a striking 71 percent ROE, yet revenue is barely growing at 1 percent a year.
We pass on the name because it fails our ethical screen on debt levels. A forward multiple of 16.8 times and a moderate moat do not offset that red flag, even with a modest gap to our fair value estimate.
The high return on equity looks impressive until you factor in the leverage behind it, and any slowdown in industrial spending could expose the thin growth rate quickly. Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MMM trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-22Markup$178.09+11.4%Entry 9
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (17 analysts) rates it buy, with a mean price target of $173.
2026-07-21Markup$159.84+0.0%Entry 8
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (17 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-20Markup$159.84+0.0%Entry 7
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (17 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-19Markup$159.84+4.0%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (17 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Markup$153.76+0.0%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (17 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-17Markup$153.76+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (17 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-16Markup$153.76+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are up 10%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (17 analysts) rates it buy, with a mean price target of $173. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-03Markup$153.76+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$153.76Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.